Quadrature Capital’s aTyr Pharma ATYR Stock Holding History

Quadrature Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,022	Closed	-$283K	–	1580
2025 Q2	$283K	Buy	+56,022	New	+$220K	﹤0.01%	707

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrature Capital's ATYR Position: Q3 2025 in Review

Quadrature Capital sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 56,022 shares — an estimated $283K sold.

Quadrature Capital first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $283K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

Quadrature Capital reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
Quadrature Capital sold 56,022 aTyr Pharma shares in Q3 2025, an estimated $283K.
Quadrature Capital first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
Quadrature Capital's aTyr Pharma position peaked at $283K in Q2 2025.
103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.